## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%); PEG 1.48 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($744.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma**
- Source: GlobeNewswire | 20251223T060159 | Bullish | Relevance: 100%
- Sanofi and Regeneron's Dupixent has been approved in Japan for children aged 6 to 11 years with severe or refractory bronchial asthma, expanding its previous approval for those 12 and older. This approval is based on Phase 3 trials showing Dupixent significantly reduced exacerbations and improved lung function in this age group. Dupixent is the first and only biologic to demonstrate improved lung function in young asthma patients in a randomized Phase 3 study, inhibiting key drivers of type 2 inflammation.

**2. Brighton Jones LLC Buys 2,335 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251224T084348 | Somewhat-Bullish | Relevance: 100%
- Brighton Jones LLC significantly increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 408.9% in Q3, acquiring 2,335 additional shares to hold a total of 2,906 shares valued at approximately $1.63 million. This increase occurred amidst recent insider selling by a VP and a Director, who offloaded substantial shares. Regeneron Pharmaceuticals reported strong Q3 earnings, surpassing expectations with $11.83 EPS on $3.75 billion in revenue, leading to analysts raising price targets and issuing "buy" or "outperform" ratings.

**3. Regeneron stock reaches 52-week high at $791.00**
- Source: Investing.com | 20251223T144911 | Bullish | Relevance: 100%
- Regeneron Pharmaceuticals Inc. (REGN) stock has reached a new 52-week high of $791.00, reflecting strong investor confidence and a "GREAT" financial health score from InvestingPro. The company's stock has seen a 9.59% increase over the past year and a 52.66% surge in the last six months, supported by management's aggressive share buyback program. Recent analyst updates show mixed sentiments with some raising price targets due to growth in products like Dupixent and strategic collaborations, while others remain cautious regarding risk/reward scenarios.

**4. Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: The Manila Times | 20251222T211557 | Neutral | Relevance: 100%
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. Pacific Time. The presentation will be accessible via Regeneron's investor relations website, with a replay and transcript archived for at least 30 days. Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases.

**5. Regeneron and Sanofi Announce Approval of Dupixent® for Asthma Treatment in Children Aged 6 to 11 in Japan**
- Source: Quiver Quantitative | 20251223T061416 | Bullish | Relevance: 96%
- Regeneron Pharmaceuticals and Sanofi announced that Japan's Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for treating severe bronchial asthma in children aged 6 to 11 years. This approval is based on Phase 3 trial data showing Dupixent significantly reduced asthma exacerbations and improved lung function, making it the first biologic to demonstrate such benefits in this age group. Dupixent is already approved in over 50 countries for pediatric asthma and targets key drivers of type 2 inflammation.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $33M sold (15 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.48 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (5 raises, avg +13%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $83.1B |
| Beta | 0.37 |
| 52W Range | $476.49 - $792.77 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.48 |
| Forward P/E | 20.4 |
| Current P/E | 18.1 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.5% to 1.5% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.58), confirming momentum. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.54% (CS: 92) | Neutral |
| RSI_14 | 67.2 | Neutral |
| MACD Histogram | 1.58 | Bullish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.134x | Above |
| vs SMA200 | 1.302x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $783.71
- **Stop Loss:** $744.91 (5.0% risk)
- **Target:** $822.51 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 30
- **Position Value:** $23,511.30
- **Portfolio %:** 23.51%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*